- Hear Dr. Vincent Rajkumar from the Mayo Clinic talk about Promising Clinical Trials in a HealthTalk webcast.
In recent years, effective treatment options were limited for people living with multiple myeloma. Now, promising clinical trials are proving very beneficial in the treatment and possible remission of multiple myeloma. In this program, Dr. Brian Durie interviews Dr. Rajkumar about ongoing clinical trials and how they could affect treatment options.
- Callisto Pharmaceuticals to Present Poster on Its Lead Drug Candidate for Multiple Myeloma at Conference on Molecular Targets and Cancer Therapeutics
"Atiprimod is a Novel Anti-Angiogenic and Anti-Cancer Drug Candidate" will be presented in Boston, November 17-20, 2003. The conference is sponsored by the American Association for Cancer Research, the National Cancer Institute and the European Organization for Research and Treatment of Cancer. (from MarketWire)
- Drives aim to add Indians to bone-marrow registry
The number of American Indians in need of a bone marrow transplant is multiplying, Yet, Statistics show that it's increasingly less likely for American Indians to find a donor match than any other race. (from the Lumberton, NC Robesonian)
- EarthTalk: Are commercial hair dyes dangerous to health?
In 1994, the Journal of the National Cancer Institute announced that deep-colored dyes (like dark brown and black), when used over a prolonged period of time, seemed to increase the risk of non-Hodgkin's lymphoma and multiple myeloma. So this is not new news, but the question keeps being asked. (from Environmental News Network)
What's New in Myeloma Research:
- Liposomal daunorubicin (DaunoXome) in multiple myeloma: a modified VAD regimen using short-term infusion.
Eucker J, Eikel D, Heider U, Jakob C, Zavrski I, Gatz F, Mergenthaler HG, Jungclas H, Possinger K, Sezer O.
In this phase I trial, 64% of the patients achieved a partial remission or a minor response.
- Farnesyltransferase inhibitors and their role in the treatment of multiple myeloma.
Santucci R, Mackley PA, Sebti S, Alsina M.
R115777 (tipifarnib) is a potent farnesyltransferase inhibitor (FTI) presently undergoing phase II/III clinical trials.
- Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy.
Coscia M, Mariani S, Battaglio S, Di Bello C, Fiore F, Foglietta M, Pileri A, Boccadoro M, Massaia M.
This vaccine formulation can overcome Id-specific immune tolerance by inducing clinical responses that are worthy of further investigation.
- Triple transplantation of autologous peripheral blood stem cells each time following conditioning with 100 mg/m2 of melphalan for multiple myeloma patients in poor performance status.
Rokicka M, Urbanowska E, Torosian T, Dwilewicz-Trojaczek J, Awedan A, Paluszewska M, Wiktor-Jedrzejczak W.
This method when developed may offer a new treatment alternative for a subgroup of high-risk multiple myeloma patients.
- More presentations scheduled for the ASH Annual Meeting, which will be held on December 6-9, 2003, in San Diego.
What's New in Clinical Trials:
(Drugs listed In alphabetical order)
- New! New active foreign sites for the randomized thal/dex study.
- SAHA (suberoylanilide hydroxamic acid)
- Phase I trial of histone deacetylase inhibitor for treatment of advanced multiple myeloma.
Cancer Trials Support Unit: A Web Based System That Offers Efficient and Effective Tools for Clinical Trials Management.
The Cancer Trials Support Unit (CTSU) is an NCI funded program to facilitate participation (by both patients and physicians) in phase III NCI sponsored Cancer treatment trials.
If you would like to browse trials currently open for enrollment, visit the Clinical Trials page of the IMF web site. Among the links, you will find CenterWatch and EmergingMed. The IMF has entered into partnerships with them to assist you in matching trials to your particular patient profile (i.e., stage of disease, previous treatment, how well you are able to carry out the activities of daily living, etc.) and by doing so, increase your chances of being eligible. You can also learn more about clinical trials by reviewing materials from the National Cancer Institute.
- Congressional Conferees Move Closer to Medicare Agreement
Conferees agreed in principle to the most contentious issues before them. Secretary of HHS Tommy Thompson commended them for their work and expressed optimism that legislation would be concluded within days.
- Write to Congress
Use this simple tool from Congress.org to help you find your representatives in Congress.
- Medicare Proposals Threaten Access to Care
Access to cancer care and treatment is threatened by the Medicare Prescription Drug Benefit legislation currently being debated by a congressional conference committee and rules proposed by the Center for Medicare and Medicaid Services (CMS).
- Appropriations Update
If the current appropriations bill is rolled into an omnibus appropriations bill, many in the cancer community are hopeful that the eventual funding increases for NIH could reach the needed 8-10 percent. But we need you to continue contacting Congress...
Quality of Life Update:
Upcoming Seminars and Conferences:
- IVth International Conference on Cancer-Induced Bone Diseases
San Antonio, Texas
December 7-9, 2003
Put on by the Paget Foundation, conference will cover the spectrum of bone metastases caused by breast cancer, prostate cancer, and osteolyic lesions due to myeloma. IMF Board Member Gregory R. Mundy, MD is Conference Chair.
- IMF Patient and Family Retreat
Ft. Lauderdale, FL
January 23-25, 2004
- IMF Patient and Family Retreat
March 12-13, 2004
- IMF Patient and Family Retreat
October 8-9, 2004
FUNdraising Made Easy
You know you want to do something, but deciding on what to do can be confusing. The IMF can help. This year, our members really rallied 'round the cause, picked up the gauntlet, and raised a lot of money for myeloma research and programs.
We are already getting calls from new members who want to join in the effort and hold an event in 2004. Suzanne Battaglia is waiting for your call. She is here to help you plan and execute your event, so please write, call or email (SBattaglia@myeloma.org) so that you can get on our Calendar of Events!
See what you can do in your community to help further the goal of finding the cure!
Items of Interest:
- Understanding Thalidomide Therapy on the Web
Read it on the web or download and print the PDF document. Available in English, Spanish, French, German, and Italian.
- The National Cancer Institute (NCI) Office of Education and Special Initiatives is looking for patients, family caregivers, and physicians who are interested in participating in telephone focus groups and in-depth interviews. Payment will be provided to all participants.
- BANK ON A CURE®
BANK ON A CURE is an innovative and powerful concept designed to establish a method to find new treatments for multiple myeloma and other related diseases as well as the possibility of new cures, while customizing care for current patients.
- Myeloma Matrix
The Myeloma Matrix provides updated information about drugs beginning with pre-clinical developments and tracks drugs as they proceed through Phases I III of clinical trials, drugs that have been FDA approved, and information on trials that are being conducted by NCI- sponsored cooperative groups as well as other myeloma study groups. The online version is updated regularly. If you would like to have a printed copy, call the toll-free hotline (800) 452-2873.
- International Prognostic Index
The International Myeloma Foundation is proud to sponsor the International Prognostic Index (IPI) Classification for Multiple Myeloma. Nearly twenty myeloma institutions from around the world are collaborating to create an updated staging system for multiple myeloma.
- NexCura Cancer Profiler
The Cancer Profiler is a free service (no hidden fees or charges). Its tools provide you with information specific to your cancer diagnosis to help you make more informed treatment decisions along with your physician.
- Expert Opinions on Multiple Myeloma
A multimedia, CME-accredited program for physicians with the chance to see world-renowned myeloma specialists sharing their knowledge, discussing treatment choices, and comparing their perspectives on controversial issues in multiple myeloma and related diseases.
- Myeloma At The Movies
It has been our goal to bring our Patient & Family Seminars to people around the country who might not be able to attend an actual meeting, so we have set up a video lending library.
- HealthTalk's Multiple Myeloma Education Network
The latest interview is Dr. Durie interviewing Dr. Rajkumar about promising IMF Clinical Trials.
Be Part of the Cure!
Many of the internet's most popular merchants will donate a portion of your purchases to the IMF if you enter their sites using the links on our Shop For The IMF page. You can also use the special shortcut URLs listed below:
So, Be Part of the Cure by using these links to the same get great service and low prices you're used to while helping support the IMF!
Help Us Help Others...
As a non-profit organization, the IMF is completely dependent on the support of our members. Please consider showing your support by making a tax-deductible donation today. Donations in honor of a friend or family member make great gifts and are a wonderful way to celebrate a special occasion. You can donate online or by calling the IMF at (800) 452-CURE. We sincerely thank you for your support.
View Back Issues Online...
New to the IMF Myeloma Minute? See what you've been missing by viewing previous issues online!
To unsubscribe from the Myeloma Minute, click here
Tell A Friend...
The Myeloma Minute is a great way to stay abreast of the latest developments within the myeloma community. We hope you'll share this information with friends, family members and physicians and encourage them to sign up for their own copy by forwarding this message. New users can register by clicking here.